Prescription medicine
Fish oil, medium-chain triglycerides, olive oil and soybean oil Brand names: Smoflipid
Fish oil, medium-chain triglycerides, olive oil and soybean oil (Smoflipid) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the fish oil, medium-chain triglycerides, olive oil and soybean oil FDA label on DailyMed (effective August 15, 2025); every fish oil, medium-chain triglycerides, olive oil and soybean oil label on DailyMed.
Highlights of the record
FDA label of August 15, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageSMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated.
Forms and strengths
- 6 g/100ml / 6 g/100ml / 5 g/100ml / 3 g/100ml
Injection (emulsion).
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 844 through July 30, 2026
What is fish oil, medium-chain triglycerides, olive oil and soybean oil used for?
From the label: indications and usageSMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
FDA pharmacologic class: Lipid Emulsion.
Source: FDA drug label (Smoflipid), Fresenius Kabi USA, LLC, effective August 15, 2025 (SPL set e0e9d917-ff6f-488e-a6a8-0ad59dd17d80), via openFDA; the full label on DailyMed
Is there a generic for fish oil, medium-chain triglycerides, olive oil and soybean oil (Smoflipid)?
No generic fish oil, medium-chain triglycerides, olive oil and soybean oil is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the fish oil, medium-chain triglycerides, olive oil and soybean oil label say about other medicines?
The fish oil, medium-chain triglycerides, olive oil and soybean oil label names 2 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Thiamine | warnings and precautions | Thiamine deficiency and fluid retention may also develop. |
| Warfarin | drug interactions | DRUG INTERACTIONS Soybean and olive oils in SMOFlipid contain vitamin K 1 which may counteract the anticoagulant activity of vitamin K antagonists such as warfarin. |
Check fish oil, medium-chain triglycerides, olive oil and soybean oil against other medicines
Source: FDA drug label (Smoflipid), Fresenius Kabi USA, LLC, effective August 15, 2025 (SPL set e0e9d917-ff6f-488e-a6a8-0ad59dd17d80), via openFDA; the full label on DailyMed
What do FAERS reports show for fish oil, medium-chain triglycerides, olive oil and soybean oil?
The FDA Adverse Event Reporting System holds 844 reports that list fish oil, medium-chain triglycerides, olive oil and soybean oil among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 101 are coded as a death and 338 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other lipid emulsions
- the pharmacologic class, with prices and generics
- Fish oil, medium-chain triglycerides, olive oil and soybean oil side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other